| BioWorld

Karo Bio Seeking SEK96M, Cutting 20 R&D Employees

Karo Bio AB is laying off 20 staff members as part of an overall effort to re-orient the company toward clinical development. (BioWorld International) Read More

FDA's Decision On Omnitrope Points To Biogeneric Haziness

Antibiotic Cage Gives Clues For Design Of New Therapies

Scientists Grow Stem Cell Line With Cystic Fibrosis Mutation

Newron Moving Safinamide Into Parkinson's Pivotal Trial

Biotechnology Industry Laments EU Indecision On GM Thresholds

Other News To Note

BioWorld Asia

Sep. 15, 2004

Karo Bio Seeking SEK96M, Cutting 20 R&D Employees

FDA's Decision On Omnitrope Points To Biogeneric Haziness

Antibiotic Cage Gives Clues For Design Of New Therapies

Scientists Grow Stem Cell Line With Cystic Fibrosis Mutation

Newron Moving Safinamide Into Parkinson's Pivotal Trial

Biotechnology Industry Laments EU Indecision On GM Thresholds

Other News To Note

Today's news in brief

Today's news in brief

News in brief

In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty